Navigation Links
Rochester Medical Reports Fourth Quarter and Year-End Results
Date:11/4/2010

his adjustment reduces net income for amounts received net of taxes paid in connection with one-time settlement of certain litigation.  These amounts were recorded in Other Income in the Statement of Operations for the fiscal year ended September 30, 2009.(2) Amortization of the intangibles acquired in June 2006 asset acquisition from Coloplast AS and Mentor Corporation.  Management believes these assets are appreciating.  This adjustment adds back amortization expense for the three and twelfth months ended September 30, 2010 and 2009 related to certain intangibles. The gross amount of amortization is $163,000 per quarter after taxes of $34,000 for a net amount of $129,000.(3) Compensation expense mandated by ASC 718.  This adjustment adds back the compensation expense recorded for stock options granted to employees and directors that vested during the three and twelve months ended September 30, 2010 and 2009.  The gross amount of compensation expense for the three months ended September 30, 2010 and 2009 is $317,000 and $295,000 net of taxes of $112,000 and $100,000 for net amounts of $205,000 and $195,000 respectively.  The gross amount of compensation expense for the twelve months ended September 30, 2010 and 2009 is $1,481,000 and $1,330,000 net of taxes of $522,000 and $452,000 for net amounts of $959,000 and $878,000 respectively.Condensed Balance Sheets(unaudited)September 30,September 30,20102009AssetsCurrent AssetsCash and equivalents

$
4,545,907$
,365,584Marketable securities

30,967,00729,896,740Accounts receivable

7,858,5406,418,656Inventories

9,240,2919,710,234Prepaid expenses and other assets

846,8991,076,183Deferred income tax

872,8491,153,964Total current assets

54,331,49354,621,361Property and equipment, net

10,017,2399,683,808Deferred income tax

1,175,052768,874Patents, net

229,106224,815Intangible assets, net

5,351,6206,017,944Goodwill4,
'/>"/>

SOURCE Rochester Medical Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
2. University of Rochester Researcher Named Millennium Pharmaceuticals Career Development Scholar of The Leukemia & Lymphoma Society
3. Rochester Medical Announces Fourth Quarter 2009 Earnings Conference Call Thursday, November 5th 2009
4. Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT(R) Insert
5. Rochester Medical Announces First Quarter 2010 Earnings Conference Call Tuesday, January 26, 2010
6. Rochester Medical Corporation Honored by Premier Healthcare Alliance for Exceptional Supplier Performance
7. AstraZeneca Joins Rochester Initiative to Further Cardiac Safety
8. Rochester Medical Announces Fourth Quarter 2010 Earnings Conference Call Thursday, November 4, 2010
9. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
10. You May Have a Thyroid Problem and Not Know It - Particularly If Youre Over 60, Says a New Harvard Medical School Report
11. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... -- According to market research report, ... & Laboratory), Industry (Food, Pharmaceutical, Biotechnology, Surgical Procedure, ... Geography - Global Trends & Forecast to 2019", ... market on the basis of various types, applications, ... market size of each of these segments in ...
(Date:9/19/2014)... , Sept. 19, 2014  Lpath, Inc. ... in bioactive lipid-targeted therapeutics, announced today that it ... registered shares of common stock and 3,605,042 unregistered ... purchase price for one registered share of common ... unregistered share of common stock will be $3.475.  ...
(Date:9/19/2014)... September 19, 2014 Aufgrund ... den äußerst erfolgreichen Serialisierungs-Countdown-Kalender aktualisiert, der jetzt auch ... PDF, verfügbar unter pharmaserialisation.com , zeigt die ... jeweils in Kraft treten. Für international ... länger um das "ob", sondern darum, "wann" sie ...
Breaking Medicine Technology:Lyophilization Market Worth $5,121.5 Million by 2019 2Lyophilization Market Worth $5,121.5 Million by 2019 3Lpath, Inc. Announces $12.5 Million Registered Direct Offering 2Lpath, Inc. Announces $12.5 Million Registered Direct Offering 3Pharma IQ stellt weltweite Serialisierungsfristen in seinen Countdown-Kalender 2014 - 2018 2
(Date:9/19/2014)... (PRWEB) September 19, 2014 Boston Scientific ... mesh lawsuit ( http://www.transvaginalmeshlawsuithelp.com/ ) that is scheduled ... month, Bernstein Liebhard LLP reports. According to ... Court, the company asserts that claims involving its Solyx ... Practice and Remedies Code, a section of which shields ...
(Date:9/19/2014)... brain structure could help predict how willing you are to ... Yale University found those with greater volume in a part ... more likely to engage in risky behavior than people with ... by the U.S. National Institute on Aging, involved two groups ... The researchers sought to determine how brain structure influences risk ...
(Date:9/19/2014)... News) -- Although there is mounting evidence that ... and older adults in the United States don,t ... new research. Less than one-quarter of adults ... the Department of Health and Human Services, the ... promoting health and fitness and staying independent, researchers ...
(Date:9/19/2014)... Alan Mozes HealthDay Reporter ... Cancer patients burdened by stress and family conflicts before ... their operation, a new study suggests. Investigators found ... have a nearly three times greater risk for complications ... of life. "We,ve long known that patient quality ...
(Date:9/19/2014)... 2014 Lipitor lawsuits ( http://www.thelipitorlawsuit.com/ ... to develop Type 2 diabetes continue to move forward ... District Court, District of South Carolina, Bernstein Liebhard LLP ... 12, 2014, discovery is underway and moving forward in ... Pfizer, Inc., the manufacturer of Lipitor, has produced millions ...
Breaking Medicine News(10 mins):Health News:Transvaginal Mesh Lawsuit Defendant Moves For Summary Judgment in Case Scheduled for Upcoming Texas Trial, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuit Defendant Moves For Summary Judgment in Case Scheduled for Upcoming Texas Trial, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuit Defendant Moves For Summary Judgment in Case Scheduled for Upcoming Texas Trial, Bernstein Liebhard LLP Reports 4Health News:Brain Structure Might Help Predict Risky Behavior 2Health News:Adults Over 45 Not Meeting U.S. Muscle Strengthening Guidelines, Study Says 2Health News:Family Squabbles Can Derail Recovery From Cancer Surgery 2Health News:Family Squabbles Can Derail Recovery From Cancer Surgery 3Health News:Lipitor Lawsuits Move Forward, as Discovery Proceeds in Federal Multidistrict Litigation, Bernstein Liebhard LLP Reports 2Health News:Lipitor Lawsuits Move Forward, as Discovery Proceeds in Federal Multidistrict Litigation, Bernstein Liebhard LLP Reports 3
... ATLANTA, Feb. 3 Brent McKenzie, based ... Consulting, the nation,s fastest growing,pharmacy benefit firm, ... Mr. McKenzie offers his clients over ... Benefits and Pharmacy Benefit Management arena.,Brent has ...
... Cancer Care Access, Efficiency and Quality; Created Based ... 3 /PRNewswire-USNewswire/ -- The National Policy ... the nation,s largest cancer treatment and research networks ... Principles for Reforming Cancer Care, designed to guide ...
... of medical research, study finds , , TUESDAY, Feb. 3 ... white parents to distrust medical research, which may explain ... So conclude University of Pittsburgh researchers who surveyed 190 ... to a primary-care clinic. , The parents were asked ...
... 2009) Green tea products have become regarded as a ... its benefit against a variety of diseases, including cancer. ... tea may counteract the anticancer effects of one cancer ... contraindicated for patients taking this medicine to ensure its ...
... study suggests that Capn4, a protein involved in cell ... after liver transplantation. Capn4 could potentially be used as ... These findings are in the February issue of ... Sons on behalf of the American Association for the ...
... popular assumptions about the health benefits of green tea, ... found that the widely used supplement renders a cancer ... lymphoma completely ineffective in treating cancer. , The ... extract (GTE) called EGCG destroys any anticancer activity of ...
Cached Medicine News:Health News:Brent McKenzie Joins ARMSRx Pharmacy Benefit Consulting 2Health News:US Oncology Adopts Principles for Reforming Cancer Care 2Health News:US Oncology Adopts Principles for Reforming Cancer Care 3Health News:Parental Distrust May Explain Lack of Black Children in Clinical Trials 2Health News:Green tea may negate the effects of a common cancer therapy 2Health News:Green tea may negate the effects of a common cancer therapy 3Health News:Protein predicts liver cancer recurrence and after transplantation 2Health News:USC study finds that green tea blocks benefits of cancer drug 2
...
A modular concept consisting of two J-Arms, to be fixed at any position of the skull clamp, allowing to the surgeon an unobstructed access to the surgical field....
Spoon end periosteal, polished finish, designed for large mucoperiosteal flaps....
Iowa University periosteal elevator, blade width 11/16" (17 mm), length 7 1/4" (184 mm)....
Medicine Products: